5 concerns over multiple cancer PBS listings

Should the rules for cancer patients on checkpoint inhibitors be different from anyone else?

Patient and drug company pressure to allow multiple cancer listings to be made at once for checkpoint inhibitors seems unlikely to be realised, with the release of a new PBAC report.

Pan weighing scales at equal height

Supporters of the move say it will make the process of listing a drug on the PBS more efficient, giving patients, particularly those with rare cancers, access to potentially effective treatments.

However, after examining the implications of allowing programmed death (ligand)-1 (PD-(L)1) checkpoint inhibitors to be subsidised for more than one cancer indication at one time,